Diabetes, the New Epidemic

Tuesday, 3 June 2014 - 1:00pm
Barnard’s Inn Hall





Overview

Worldwide prevalence of type 2 diabetes is rapidly increasing with the numbers projected to rise to 366 million in 2030. Risk of diabetes is even larger, since 30-50% of people are affected by obesity or pre-diabetes which may eventually progress to diabetes and/or risk of cardiovascular diseases. This can be reversible and early intervention (weight loss, exercise programmes or pharmacological) can reduce risk, but adherence and costs are an issue. Less conventional approaches such as increasing taxes on unhealthy food, financial incentives or peer-monitoring have also been proposed and Government, private institutions and media should all collaborate to fight this epidemic.

 






Transcript of the lecture

3 June 2014

 

Diabetes, the New Epidemic

 

Professor Paolo Pozzilli MD

 

Diabetes is spreading worldwide and it is rapidly becoming a new epidemic threat for the 3rd millennium. Its natural history is related to long-term complications that impact life quality (complications such as retinopathy, nephropathy, and neuropathy) and life expectancy (macrovascular disease) (1). Diabetes, therefore, imposes a large and growing burden on public health worldwide.

 

In 2007, over 246 million people were diagnosed with diabetes, and future projections indicate a significant increase in the next decades. It has been reported that by the 2035 there will be more than 470 million people with diabetes worldwide, with the highest rates of increase in the developing countries. In these regions, diabetes will affect over 228 million subjects, twice as many as in the western countries (1).

 

Why did type 2 diabetes become pandemic?

 

The prevalence of obesity, a known risk factor for type 2 diabetes, has dramatically increased over the years, especially among children and adolescents. The number of overweight children under the age of 5 years is estimated to be over 42 millions worldwide. Rates of childhood obesity have greatly increased between 1980 and 2010 (2). Currently, 10% of children worldwide are either overweight or obese (3). Childhood obesity is already epidemic in some areas and rising in others.The diabetic and obesity epidemics will be the major drains on healthcare budgets in 10 years from now and it is crucial to reverse this trend in childhood obesity.

 

Unfortunately, obesity is often neglected and still not fully recognized as a disease by the people. On the other hand, diabetes remains undiagnosed for years– according to the NHANES survey conducted in the United States, diabetes was undiagnosed in 30% of screened population (4); importantly, over 25% of patients newly diagnosed with diabetes showed already established diabetic retinopathy or microalbuminuria, a marker of kidney injury (5, 6).

 

Diabetes is preceded by intermediate subclinical stages, commonly defined as prediabetes, comprising the categories of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Pre-diabetes stages represent abnormal metabolic states, conferring a high risk to progress to diabetes or its complications (7, 8). Clinical intervention studies have shown that prediabetic status is reversible and an early intervention may delay the final deterioration of glucose homeostasis. Therefore its early detection is crucial to reduce the risk to develop the disease (9).

 

Can type 2 diabetes be prevented or delayed?

 

Effect of lifestyle changes

 

Weight gain and sedentary lifestyle are two main pathophysiological elements linked to diabetes development. Both conditions may alter glucose homeostasis by impairing insulin production and/or action on target tissues. Several trials have shown that lifestyle changes based on weight loss and physical activity may reduce the risk of type 2 diabetes (table 1).

 

In the Diabetes Prevention Program (DPP), carried out on 3,234 subjects at risk for diabetes (overweight with IGT), a lifestyle-modification program with the goals of at least a 7 % weight loss and at least 150 minutes of physical activity per week reduced the risk of type 2 diabetes by 58% (10).

 

In the Finnish Diabetes Prevention Study (DPS), 522 middle-age overweight subjects with IGT were randomly assigned to either control or intervention program consisting in receiving individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fats and increasing intake of fiber and physical activity. During the study, diabetes risk was reduced by 58 % in the intervention group and directly associated with changes in lifestyle (11).

 

The China Da Quing Diabetes Prevention Study (CDQDPS) compared the efficacy of different lifestyle changes approaches (diet and physical activity alone, or combined). After six years, the intervention strategies reduced significantly the risk of type 2 diabetes  compared with the control group (by 48% in diet group, 41% in the physical activity group, 46% in the combined approach) (12). These results confirmed the efficacy of lifestyle changes even in individuals with clinical and ethnic features different from those in the DPP and DPS.

 

Effect of pharmacological intervention

 

Pharmacological intervention may prevent type 2 diabetes (table 2). However, their use as an alternative strategy to lifestyle changes is limited due to the lack of long-term sustained effect, as well as by the higher costs and the increased risk of adverse events compared to non-pharmacological intervention.

 

Metformin. Metformin acts as an insulin-sensitizer and it is the only drug approved for type 2 diabetes prevention in subjects with prediabetes. The DPP showed that treatment with metformin (850 mg twice daily) reduced diabetes incidence by 31 % compared with the control group. However, the same trial also showed that lifestyle was more effective than metformin (10). In the Indian Diabetes Prevention Program (IDPP), carried out on 531 subjects of Indian ethnicity with IGT, a lower dose of 500 mg daily was equally effective in reducing diabetes risk but no synergistic effect was evident for combined treatment with metformin and lifestyle (13).

 

 

 

Alpha-glucosidase inhibitors (AGI). AGIs lower blood glucose by reducing carbohydrate processing in the bowel and therefore glucose absorption. The STOP-NIDDM trial on 1,419 subjects with IGT has shown that acarbose reduced significantly the risk of type 2 diabetes by 25% compared with the placebo control group (14). Moreover, hypertension and cardiovascular events were reduced by 34% and 49%, respectively (15). Similar efficacy was obtained by voglibose with a 40.5% risk reduction over three years of treatment (16).

 

Thiazolidinediones (TZD).  TZDs increase insulin action on target tissues by enhancing activity of their receptor PPAR-γ. The DREAM study (17)showed that rosiglitazone (8 mg daily) reduced type 2 diabetes incidence by 62% over three years; however, this effect was not durable and the concern on cardiovascular safety raised by observational and post-hoc analysis (18, 19)has led the EMA to rosiglitazone withdrawal. Also the other TZD, pioglitazone, has shown to be effective in reducing diabetes incidence in 600 subjects with IGT, but adverse events such as weight gain and oedema were higher in the intervention group compared with the placebo (20).

 

Insulin.Recently, the ORIGIN study carried out on more than 12,000 people evaluated the effect of insulin glargine on diabetes risk. Treatment with glargin reduced type 2 diabetes by 20% but it was associated with increased risk of hypoglycaemic events and weight gain compared with the control group (21).

 

Do prevention interventions have sustained effects?

 

According to a follow-up analysis of the DPP, lifestyle may have sustained effect on diabetes prevention for a period as long as ten years; in this study, people previously on lifestyle changes had a sustained 34% reduction of type 2 diabetes, despite 5 kg body weight re-gain (22). In the seven years post-trial of the DPS a sustained effect of lifestyle was also evident– 21% risk reduction of developing type 2 diabetes (23). The benefit of lifestyle was durable for 14 years in the CDQDPS (24).  On the contrary, among the pharmacological interventions, only metformin induces a sustained effect on diabetes prevention, while other drugs failed.

 

Can diabetes prevention be feasible?

 

Although clinical trials have shown that diabetes can be prevented or delayed, the number of people diagnosed with this disease is increasing worldwide, suggesting the difficulty to deliver prevention strategies in real life setting. Indeed, a recent analysis on the Italian population revealed that only 2% of people perceive diabetes as a serious disease eventually leading to death.

Data from the Food and Agriculture Organization of the United Nations show that caloric intake pro capite has grown by 30% in the last 40 years and that this is mainly related to increased intake of fat-enriched food. In parallel, price of food has significantly reduced over time. In particular, price of added sugars has dropped significantly more than the price of healthful foods (25).

It is well known that price is an important determinant of food choices and diet, suggesting that increasing the price of unhealthy foods, by taxation, should reduce consumption of the taxed foods. In the past years, several countries such as Denmark, France, Hungary and Peru have introduced taxes for unhealthy food items, and others countries are considering such taxes. Some of these taxes are small excise taxes levied on sugar sweetened beverages or either goods and services taxes, levied on junk food (26). A 20 years longitudinal study on 5,115 young adults has shown that 10% taxes on sugar soda and

 

pizza was able to reduce caloric intake by 7 and 10%, respectively; importantly, this was associated with significant weight loss and reduced insulin levels during the 20 years after the introduction of food taxes

(27). However additional evidence is needed to evaluate the cost-effectiveness of this strategy on obesity and type 2 diabetes risk.

Moreover, a recent trial has shown that the use of economic incentives produced significant weight loss (more than the control group) during a 16 weeks intervention (28). Another study showed similar results but it highlighted  higher efficacy in terms of body weight changes for group-based incentives rather than individual incentives (29).However, such benefits were not fully sustained after study ending, suggesting that further studies are needed to evaluate this strategy in diabetes and obesity prevention.

Conclusions

Diabetes is a global issue. Intervention trials have shown that modest lifestyle changes can reduce significantly the rate of type 2 diabetes in patients at highest risk. Lifestyle changes have proven sustained effects over time, are safe, easy to deliver and less expensive than pharmacological approaches. However, barriers such as misconception of diabetes as serious disease by the people, reduced adherence to treatments and lack of community programs to support prevention –especially in developing countries– limit the feasibility of these approaches in real life settings.

Diabetes prevention requires social and political changes. Novel, additional and cost-effective strategies that can be easily delivered and accepted by the community are needed.

 

Table 1 – Lifestyle changes can prevent type 2 diabetes.

 

  Trial   N   Population   Follow-up     

  (years)

  Intervention   RR     

  (95% CI)

  Da Qing   577   IGT     

  (China)

  6   1. Diet     

  2. Exercise

  3. Diet & Exercise

  0.66 (0.53-0.81)     

  0.56 (0.44-0.70)

  0.49 (0.33-0.73)

  DPS   522   IGT     

  overweight

  (Finland)

  3.2   Diet & Exercise   0.42 (0.3-0.7)
  DPP   3,234   IGT     

  (USA)

  2   1. Diet & Exercise     

  2. Metformin

  0.42 (0.34-0.52)     

  0.69 (0.57-0.83)

  IDPP   531   IGT     

  (India)

  2.5   1. Diet & Exercise     

  2. Metformin

  3. Metformin + Diet & Exercise

  0.72 (0.62-0.80)      

  0.74 (0.65-0.81)

  0.72 (0.62-0.80)

 

DPS, Finnish Diabetes Prevention Study; DPP, Diabetes Prevention Program; IDPP, Indian Diabetes Prevention Program; RR, relative risk, CI, confidence interval

 

 

 

 

 

Tabella 2 – Pharmacological intervention for type 2 diabetes prevention.

  Trial   N   Population   Drug  Follow-up     

  (years)

  RR     

  (95% CI)

Weight changes

Adverse events

  DPP   3,234 IGR       

Overweight

  Metformin     

  (850 mg bid)

  2.8   0.69     

  (0.57-0.83)

  ↓   GI simptoms
  STOP-NIDDM   1,419   IGT   Acarbose     

  (100 mg tid)

  3.9   0.75     

  (0.63-0.90)

    GI simptoms
  Voglibose   1,780   IGT   Voglibose     

  (0.2 mg tid)

  3   0.59     

  (0.43-0.81)

    GI simptoms
  DREAM   5,269   IGR Rosiglitazone        

(8mg daily)

  3   0.40     

  (0.35-0.46)

  ↑   Oedema
  ACT-NOW   602   IGT   Pioglitazone     

  (30-45mg daily)

  2.4   0.28     

  (0.16-0.49)

  ↑   Oedema,         

  Dyslipidemia

  XENDOS   3,277   IGT overweight   Orlistat     

  (120mg tid)

  4   0.72     

  (0.58-0.91)

  ↓   GI simptoms
  ORIGIN   1,456   IGR   Glargine   6   0.80*     

  (0.64-1.00)

  ↑   Hypoglycemia

 

* Odds Ratio; IGR, Impaired glucose regulation; GI, Gastro-intestinal; RR, relative risk; CI, confidence interval

 

 

References

 

1.          www.idf.org.

2.          Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.

3.          Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010 May 15;375(9727):1737-48.

4.          Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 2006 Jun;29(6):1263-8.

5.          The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007 Feb;24(2):137-44.

6.          Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992 Jul;15(7):815-9.

7.          Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007 Dec;78(3):305-12.

8.          Charpentier G, Riveline JP, Dardari D, Varroud-Vial M. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? Drugs. 2006;66(3):273-86.

9.          Palermo A, Maggi D, Maurizi AR, Pozzilli P, Buzzetti R. Prevention of type 2 diabetes mellitus: is it feasible? Diabetes Metab Res Rev. 2014 Mar;30 Suppl 1:4-12.

10.        Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.

11.        Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.

12.        Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44.

13.        Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006 Feb;49(2):289-97.

14.        Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072-7.

15.        Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003 Jul 23;290(4):486-94.

16.        Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607-14.

17.        Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.

18.        Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010 Jul 28;304(4):411-8.

19.        Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.

20.        DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24;364(12):1104-15.

21.        Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28.

22.        Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86.

23.        Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9.

24.        Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008 May 24;371(9626):1783-9.

25.        FAO Statistics Division 2010 FBS, Food and Agriculture Organization of the United Nations, viewed June, 2014, http://faostat.fao.org/.

26.        Mytton OT, Clarke D, Rayner M. Taxing unhealthy food and drinks to improve health. BMJ. 2012;344:e2931.

27.        Duffey KJ, Gordon-Larsen P, Shikany JM, Guilkey D, Jacobs DR, Jr., Popkin BM. Food price and diet and health outcomes: 20 years of the CARDIA Study. Arch Intern Med. 2010 Mar 8;170(5):420-6.

28.        Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA. 2008 Dec 10;300(22):2631-7.

29.        Kullgren JT, Troxel AB, Loewenstein G, Asch DA, Norton LA, Wesby L, et al. Individual- versus group-based financial incentives for weight loss: a randomized, controlled trial. Ann Intern Med. 2013 Apr 2;158(7):505-14.

 

                                                                                            © Professor Paolo Pozzilli MD, 2014